{"ATC Code":"A04AD01","Abbreviation":[],"Adverse Effects":"The most commonly reported side effects of scopolamine patch use are blurred vision, dilated pupils, and dry mouth. The vision disturbances are most often due to inadequate handwashing techniques after the application of the patch. Less frequently reported side effects are related to anticholinergic toxidrome: flushed skin, tachycardia, agitation, and confusion. These side effects are usually mild and quick to resolve after patch removal. If needed, the clinician can administer a reversal agent like physostigmine if a side effect persists.","Aliases":["Scopace","Boro-Scopol","RefChem:570028","Hyoscine","51-34-3","Scopine (-)-tropate","Scopine tropate","6,7-Epoxytropine tropate","Atrochin","Atroquin","Transderm-Scop","Epoxytropine tropate","Isopto Hyoscine","Hyosol","Scopolamine hydrobromide","Beldavrin","Scopamin","α-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester","Skopolamin","Scop","Tropic acid, ester with scopine","Tranaxine","(1S,3S,5R,6R,7S)-6,7-epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate","Hysco","Hyoscine bromide"],"Biological Half-Life":"The half-life of scopolamine differs depending on the route. Intravenous, oral, and intramuscular administration have similar half-lives of 68.7 ± 1.0, 63.7 ± 1.3, and 69.1 ±8/0 min, respectively. The half-life is greater with subcutaneous administration at 213 min. Following removal of the transdermal patch system, scopolamine plasma concentrations decrease in a log-linear fashion with a half-life of 9.5 hours.","CAS":"114-49-8","ChEBI":"CHEBI:16794","ChEMBL":"CHEMBL3084722","ChemicalClasses":["tropane"],"Chirality":"absolute","Color/Form":"Viscous liquid","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Adjuvants, Anesthesia; Mydriatics; Muscarinic Antagonists; Parasympatholytics","Drug Indication":"Scopolamine is indicated in adult patients for the prevention of nausea and vomiting associated with motion sickness and for the prevention of postoperative nausea and vomiting (PONV) associated with anesthesia or opiate analgesia.","Drug Warnings":"The use of scopolamine to produce tranquilization and amnesia in a variety of circumstances, including labor, is declining and of questionable value. Given alone in the presence of pain or severe anxiety, scopolamine may induce outbursts of uncontrolled behavior.","DurationOfAction":"","EINECS":"200-090-3","EliminationHalfLife":"5 hours","Esters":[],"European Community (EC) Number":"200-090-3","FDA Pharmacological Classification":"DL48G20X8X","Formating":[],"HeavyAtomCount":22,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Adjuvants, Anesthesia; Mydriatics; Muscarinic Antagonists; Parasympatholytics","IUPACName":"[(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate","InChI":"InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1","InChIKey":"STECJAGHUSJQJN-USLFZFAMSA-N","Interactions":"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. Special attention should be paid to potential interactions with drugs having anticholinergic properties; e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.","LD50":[{"dosages":[{"amount":"2650 mg/kg","route":"oral"}],"organism":"Rat"},{"dosages":[{"amount":"1275 mg/kg","route":"oral"},{"amount":"400 mg/kg","route":"intraperitoneal"},{"amount":"1700 mg/kg","route":"subcutaneous"},{"amount":"100 mg/kg","route":"intravenous"}],"organism":"Mouse"}],"LDLo":[{"dosages":[{"amount":"75 mg/kg","route":"subcutaneous"},{"amount":"50 mg/kg","route":"intravenous"}],"organism":"Rabbit"}],"MeSH Pharmacological Classification":"Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage.","Melting Point":"387 °","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e21\u003c/sub\u003eNO\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"303.35 g/mol","Opticalactivity":"UNSPECIFIED","Pharmacodynamics":"Scopolamine is an anticholinergic belladonna alkaloid that, through competitive inhibition of muscarinic receptors, affects parasympathetic nervous system function and acts on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Formulated as a patch, scopolamine is released continuously over three days and remains detectable in urine over a period of 108 hours. Scopolamine is contraindicated in angle-closure glaucoma and should be used with caution in patients with open-angle glaucoma due to scopolamine's ability to increase intraocular pressure. Also, scopolamine exhibits several neuropsychiatric effects: exacerbated psychosis, seizures, seizure-like, and other psychiatric reactions, and cognitive impairment; scopolamine may impair the ability of patients to operate machinery or motor vehicles, play underwater sports, or perform any other potentially hazardous activity. Women with severe preeclampsia should avoid scopolamine. Patients with gastrointestinal or urinary disorders should be monitored frequently for impairments, and scopolamine should be discontinued if these develop. Scopolamine can cause blurred vision if applied directly to the eye, and the transdermal patch should be removed before an MRI procedure to avoid skin burns. Due to its gastrointestinal effects, scopolamine can interfere with gastric secretion testing and should be discontinued at least 10 days before performing the test. Finally, scopolamine may induce dependence and resulting withdrawal symptoms, such as nausea, dizziness, vomiting, gastrointestinal disturbances, sweating, headaches, bradycardia, hypotension, and various neuropsychiatric manifestations following treatment discontinuation; severe symptoms may require medical attention.","Physical Description":"Scopolamine hydrobromide appears as colorless crystals or white powder or solid. Has no odor. pH (of 5% solution): 4-5.5. Slightly efflorescent in dry air. Bitter, acrid taste. (NTP, 1992)","PubChemId":3000322,"Record Description":["LiverTox|Gastroinestinal|Antiemetic|Anticholinergic"],"RefCount":4,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Scopolamine","Name":"Scopolamine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q27165268","Name":"Scopolamine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00747","Name":"Scopolamine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3000322","Name":"Scopolamine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3084722","Name":"Scopolamine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16794","Name":"Scopolamine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=114-49-8","Name":"Scopolamine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/DL48G20X8X","Name":"Scopolamine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6023573","Name":"Scopolamine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3000322, Scopolamine. Accessed September 14, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3000322\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3000322\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Scopolamine. UNII: DL48G20X8X. Global Substance Registration System. Accessed September 14, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/DL48G20X8X\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/DL48G20X8X\u003c/a\u003e","Poisons Standard October 2020. September 30, 2020. Accessed September 14, 2025. \u003ca href=https://www.legislation.gov.au/Details/F2020L01255\u003ehttps://www.legislation.gov.au/Details/F2020L01255\u003c/a\u003e"],"SMILES":"CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4","SaltData":[{"AcidCount":1,"Amine":"Scopolamine","AmineCount":2,"Formula":"OS(=O)(=O)O","Name":"hemisulfate","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 116.729 124.052\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h117v125H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m25.235 115.953 2.848-15.976\" class=\"bond\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"m46.109 92.834-.145-.685-14.254 1.572.365 1.727.366 1.726z\" class=\"bond\"/\u003e\u003cpath d=\"m46.037 92.491-3.455-14.834M42.582 77.657l-13.716-6.604M28.866 71.053 15.15 77.657M15.15 77.657l-3.352 14.834\" class=\"bond\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"m11.871 92.149-.147.684 13.361 4.322.37-1.72.371-1.719z\" class=\"bond\"/\u003e\u003cpath d=\"m11.798 92.491 9.448 11.887\" class=\"bond\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M21.246 104.728a.376.376 0 0 1-.35-.35c0-.175.175-.35.35-.35h5.094l-.117.7zm6.932 0 .118-.7h8.19q.051-.048.099-.047c.137 0 .251.256.251.397 0 .175-.175.35-.35.35z\" class=\"bond\"/\u003e\u003cpath d=\"m46.037 92.491-9.551 11.887\" class=\"bond\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"m36.789 104.553-.606-.35-6.776 9.141 1.427.824 1.428.824zM26.568 114.355l.461-2.76 1.295 1.746-1.427.824zm-1.794-.969-3.831-8.833.606-.35 3.885 5.24z\" class=\"bond\"/\u003e\u003cpath d=\"M28.866 71.053V59.735M32.145 53.921l9.92-5.728\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m42.065 46.786 10.524 6.076M40.845 48.897l10.524 6.076\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m52.589 52.862-5.262-3.038M51.369 54.973l-5.262-3.038\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"M42.065 48.193v-15.24\" class=\"bond\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"m41.89 32.65.35.607 13.373-5.851v-4.872z\" class=\"bond\"/\u003e\u003cpath d=\"M55.263 25.333V14.015M42.065 32.953l-13.199-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m15.663 32.962 13.203-7.629M15.663 30.146l10.765-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m15.663 32.962-13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m2.47 10.093-.005 15.249M4.908 11.501l-.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m2.47 10.093 13.203-7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m28.871 10.085-13.198-7.62M26.432 11.493 15.673 5.281\"/\u003e\u003c/g\u003e\u003cpath d=\"m28.866 25.333.005-15.248\" class=\"bond\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M30.705 98.598h-.72l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566v-4.899h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482v-2.768h.577z\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M31.126 117.574q0 .756-.256 1.327-.256.566-.756.881-.501.316-1.245.316-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.566.756-.881t1.274-.316q.732 0 1.233.316.5.309.756.875t.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M31.126 55.81q0 .757-.256 1.328-.256.566-.756.881-.501.316-1.245.316-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.751.244-1.31.25-.566.756-.881t1.274-.316q.732 0 1.233.316.5.309.756.875.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.459 0-.928-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.452M57.522 55.81q0 .757-.256 1.328-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.751.244-1.31.25-.566.756-.881t1.274-.316q.732 0 1.232.316.5.309.756.875.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.459 0-.928-.387-1.452-.381-.524-1.208-.524-.834 0-1.227.524t-.393 1.452\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M57.522 10.09q0 .757-.256 1.328-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.751.244-1.31.25-.566.756-.881t1.274-.316q.732 0 1.232.316.5.309.756.875.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.459 0-.928-.387-1.452-.381-.524-1.208-.524-.834 0-1.227.524t-.393 1.452M61.828 12.543h-.619v-2.286h-2.512v2.286h-.613V7.644h.613v2.071h2.512V7.644h.619z\"/\u003e\u003c/g\u003e\u003cpath fill=\"none\" d=\"M3.303 122.003H.56V.56h2.743M60.99 122.003h2.743V.56H60.99\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M67.448 123.492h-1.943v-.3l.771-.779q.222-.221.372-.393.153-.175.232-.339.079-.168.079-.364 0-.243-.147-.368-.143-.129-.371-.129-.215 0-.379.075-.161.075-.329.208l-.192-.243q.171-.147.392-.247.226-.1.508-.1.41 0 .65.207.239.208.239.575 0 .229-.096.433-.093.2-.265.396-.168.197-.393.418l-.614.604v.017h1.486z\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m28.083 99.977-1.424 7.988\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m25.235 115.953 1.424-7.988M28.866 59.735v5.659M32.145 53.921l4.96-2.864M55.263 14.015v5.659M55.263 14.015v5.659\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m90.792 67.753 7.176-4.143\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m102.799 59.413 7.22-4.169M104.018 61.525l7.221-4.169\"/\u003e\u003cpath stroke=\"#c6c62c\" d=\"m102.799 59.413 3.61-2.085\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m110.019 55.244-3.61 2.084\" class=\"hi\"/\u003e\u003cpath stroke=\"#c6c62c\" d=\"m104.018 61.525 3.611-2.084\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m111.239 57.356-3.61 2.085\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m97.762 59.356-3.76-6.512M99.874 58.137l-3.76-6.513\"/\u003e\u003cpath stroke=\"#c6c62c\" d=\"m97.762 59.356-1.88-3.256\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m94.002 52.844 1.88 3.256\" class=\"hi\"/\u003e\u003cpath stroke=\"#c6c62c\" d=\"m99.874 58.137-1.88-3.257\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m96.114 51.624 1.88 3.256\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m102.602 65.3 3.76 6.513\" class=\"bond\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M89.773 69.643q0 .756-.256 1.328-.256.565-.756.881-.501.315-1.245.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.233.315.5.31.756.876.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.529 1.22.529.84 0 1.221-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452M84.692 72.096h-.619V69.81h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#c6c62c\" stroke=\"none\" d=\"M102.256 63.163q0 .649-.476 1.018-.47.363-1.268.363-.417 0-.768-.065-.345-.06-.577-.173v-.589q.244.113.607.202.369.089.762.089.548 0 .827-.214.28-.214.28-.577 0-.238-.107-.399-.101-.167-.351-.31t-.697-.297q-.625-.227-.946-.554-.316-.333-.316-.899 0-.393.197-.667.202-.28.553-.428.358-.155.816-.155.405 0 .738.077.339.072.613.197l-.196.53q-.25-.114-.548-.185-.297-.077-.625-.077-.458 0-.69.196-.233.197-.233.518 0 .244.102.411.107.166.339.297.232.125.631.28.429.155.726.34.298.178.453.434.154.25.154.637\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M116.169 54.403q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.876.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.529 1.221.529.839 0 1.22-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.208-.524-.834 0-1.227.524-.393.523-.393 1.452M95.351 48.825q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.263-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.507-.315 1.274-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .923.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.535.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M110.591 75.221q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.244.315-.756 0-1.263-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.881.507-.316 1.274-.316.733 0 1.233.316.5.309.756.875.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.459 0-.928-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.452M114.897 77.674h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.071h2.512v-2.071h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m90.792 67.753 3.588-2.072M90.792 67.753l3.588-2.072\" class=\"hi\"/\u003e\u003cpath stroke=\"#c6c62c\" d=\"m97.968 63.61-3.588 2.071M102.602 65.3l1.88 3.256\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m106.362 71.813-1.88-3.257\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Scopolamine hemisulfate","UNII":"SU7QP314L1"}],"Salts":["hemisulfate"],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S4 substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"}],"Solubility":"greater than or equal to 100 mg/mL at 68 °F (NTP, 1992)","Stability/Shelf Life":"The commercially available transdermal system of scopolamine should be stored at controlled room temperature between 20 and 25 °C. Scopolamine hydrobromide should be stored in tight, light-resistant containers. Scopolamine hydrobromide injections should be stored in light-resistant, single-dose or multiple-dose containers, preferably of USP Type I glass, at 15 to 30 °C; freezing of the injections should be avoided. Commercially available scopolamine hydrobromide soluble tablets should be stored at controlled room temperature (15 to 30 °C).","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 60.961 119.231\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h61v120H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m23.809 114.527 2.847-15.977\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"m44.682 91.407-.145-.685-14.254 1.572.365 1.727.366 1.726z\" class=\"bond\"/\u003e\u003cpath d=\"m44.61 91.064-3.454-14.833M41.156 76.231 27.44 69.627M27.44 69.627l-13.716 6.604M13.724 76.231l-3.353 14.833\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"m10.444 90.722-.147.684 13.361 4.322.37-1.72.371-1.719z\" class=\"bond\"/\u003e\u003cpath d=\"m10.371 91.064 9.449 11.887\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M19.82 103.302a.38.38 0 0 1-.351-.351c0-.175.175-.35.351-.35h5.093l-.117.701zm6.932 0 .117-.701h8.191q.05-.048.099-.047c.136 0 .251.256.251.397 0 .175-.175.351-.35.351z\" class=\"bond\"/\u003e\u003cpath d=\"m44.61 91.064-9.55 11.887\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"m35.363 103.126-.607-.35-6.776 9.141 1.427.824 1.428.824zM25.141 112.928l.462-2.76 1.294 1.746-1.427.824zm-1.794-.969-3.831-8.833.607-.35 3.884 5.24z\" class=\"bond\"/\u003e\u003cpath d=\"M27.44 69.627V58.308M30.718 52.494l9.92-5.727\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m40.638 45.359 10.524 6.076M39.419 47.471l10.524 6.076\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M51.162 51.435 45.9 48.397M49.943 53.547l-5.262-3.038\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"M40.638 46.767v-15.24\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"m40.463 31.224.35.606 13.373-5.851v-4.872z\" class=\"bond\"/\u003e\u003cpath d=\"M53.836 23.907V12.588M40.638 31.527l-13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.236 31.535 13.204-7.628M14.236 28.719l10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.236 31.535-13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.043 8.667-.005 15.248M3.481 10.074l-.004 12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.043 8.667 13.203-7.629\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.444 8.658-13.198-7.62M25.006 10.066 14.247 3.854\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.44 23.907.004-15.249\" class=\"bond\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M29.279 97.172h-.721l-2.619-4.066h-.03l.03.595q.024.357.024.732v2.739h-.566v-4.9h.715l2.607 4.054h.03l-.018-.327-.024-.476q-.006-.262-.006-.483v-2.768h.578z\" class=\"atom\"/\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M29.699 116.147q0 .756-.256 1.327-.256.566-.756.881t-1.245.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M29.699 54.384q0 .756-.256 1.327-.256.566-.756.881t-1.245.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M56.095 54.384q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .922.387 1.458.392.53 1.22.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.226.524-.393.524-.393 1.453\" class=\"atom\"/\u003e\u003cg fill=\"#ff0d0d\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M56.095 8.664q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .922.387 1.458.392.53 1.22.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.226.524-.393.524-.393 1.453M60.401 11.116h-.619V8.83H57.27v2.286h-.613V6.217h.613v2.072h2.512V6.217h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#3050f8\" d=\"m26.656 98.55-1.423 7.988\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m23.809 114.527 1.424-7.989M27.44 58.308v5.66M30.718 52.494l4.96-2.864M53.836 12.588v5.659M53.836 12.588v5.659\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","TDLo":[{"dosages":[{"amount":"2 μg/kg","route":"subcutaneous"},{"amount":"4 μg/kg","route":"intramuscular"}],"organism":"Human"},{"dosages":[{"amount":"14 μg/kg","route":"subcutaneous"},{"amount":"24 μg/kg","route":"intramuscular"}],"organism":"Human - male"},{"dosages":[{"amount":"13 μg/kg","route":"subcutaneous"}],"organism":"Human - female"}],"Therapeutic Uses":"Adjuvants, Anesthesia; Antiemetics; Muscarinic Antagonists; Mydriatics; Parasympatholytics","Title":"Scopolamine","UNII":"DL48G20X8X","Wikidata":"Q27165268","Wikipedia":"Scopolamine","XLogP":0.9}